IP Library Granted Patent US 8,679,530
Granted Patent B2
US 8,679,530 · App. 12/092,628 · Granted Mar 25, 2014

Liposomally encapsulated reduced glutathione, including with other pharmacologic preparation, capable of administration as an oral, topical, intraoral or transmucosal, prepartion, for reversal and prevention of oxidation of cholesterol and of low density lipoprotein

Inventors: F. Timothy Guilford (Palo Alto, CA); Brooke Schumm, III (Ellicott City, MD)
Assignee: Your Energy Systems, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,679,530
App. No.
12/092,628
Granted
Mar 25, 2014
Kind
B2
Abstract

The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.

Claims (3)

1. A pharmaceutical composition for treatment of vascular disease in a mammalian patient, comprising:

reduced glutathione in a liposomal formulation capable of administration orally, dermally or mucosally, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; and

a cholesterol lowering agent chosen from the group of drugs known as statins.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2017
From: SCHUMM, BROOKE, III
To: YOUR ENERGY SYSTEMS, LLC
Reel/Frame 042530/0089 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 22, 2014
From: GUILFORD, F. TIMOTHY
To: YOUR ENERGY SYSTEMS, LLC
Reel/Frame 032016/0566 →
Continuity (5)
Continuation In Part 11230277 · Sep 20, 2005
Continuation In Part 11163979 · Nov 6, 2005
Provisional Application 60863015 · Oct 26, 2006
Provisional Application 60522785 · Nov 7, 2004
Related Publication 20110129523A1 · Jun 2, 2011